Cargando…
Antibody response to the BNT162b2 vaccine in maintenance hemodialysis patients
Autores principales: | Attias, Philippe, Sakhi, Hamza, Rieu, Philippe, Soorkia, Arvish, Assayag, David, Bouhroum, Sabrina, Nizard, Patrice, El Karoui, Khalil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Society of Nephrology. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055946/ https://www.ncbi.nlm.nih.gov/pubmed/33887317 http://dx.doi.org/10.1016/j.kint.2021.04.009 |
Ejemplares similares
-
Kinetics of Anti–SARS-CoV-2 IgG Antibodies in Hemodialysis Patients Six Months after Infection
por: Sakhi, Hamza, et al.
Publicado: (2021) -
Vaccination anti-COVID-19 chez les patients dialysés et transplantés rénaux
por: Sakhi, Hamza, et al.
Publicado: (2021) -
Long-term Antibody Response to the BNT162b2 Vaccine Among Maintenance Hemodialysis Patients
por: Nacasch, Naomi, et al.
Publicado: (2022) -
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022) -
Treatment impact on COVID-19 evolution in hemodialysis patients
por: Chawki, Sylvain, et al.
Publicado: (2020)